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Summary
Nearly one-third ofIgM antilymphocyte autoantibody-positive sera from patients with systemic
lupus erythematosus (SLE) contain IgM antibodies to one or more 180-220-kD molecules (p180,
p190, p205, and p220) in blots of glycoproteins purified from T cells by wheat germ agglutinin
affinity chromatography . Identity of these IgM targets with multiple isoforms of CD45 was
established by their specific depletion from T cell glycoproteins by immunoprecipitation with
T191, a monoclonal antibody (mAb) that reacts with an epitope common to all CD45 isoforms .
Although the anti-CD45 autoantibodies recognize higher molecular weight isoforms primarily,
antigenic specificity in this system is quite heterogeneous and includes multiple distinct CD45
isoforms on different types ofT cells that are, at least in part, different from those reactive with
mAbs 2144 and UCHL1 . Because CD45 is a major membrane protein tyrosine phosphatase that
plays a critical role in antigen-inducedT cell activation, the present data may be relevant to some
of the antilymphocyte antibody-mediated immunologic abnormalities that characterize SLE and
related autoimmune diseases.
S tudy of the cell-type specificity of IgM antilymphocyte
autoantibodies (cold lymphocytotoxins) in SLE has es-
tablished an overall preferential reactivity with peripheral
CD4+ T cells expressing high levels of CD45RA isoforms
defined by monoclonal anti-2144 (suppressor-inducer pheno-
type) (1, 2) and with activated T cells (3) . Observations in
this system further suggest that such autoantibodies deplete
circulating CD4+/CD45RA+ T cells in patients with ac-
tive disease and inhibit antigen-induced T cell proliferation
and suppressor-inducer function in polyclonal B cell activa-
tion in vitro (2-4) . Collectively, the available data argue that
autoantibodies to lymphocytes contribute substantially to the .
complex immunoregulatory abnormalities that characterize
patients with SLE and related systemic autoimmune disorders
(5, 6) . Progress in this area has been limited, however, by
the paucity of unambiguous information concerning the mo-
lecular nature of the target antigens involved . In the present
investigation, several -200-kD glycoproteins shown previ-
ously to be IgM antilymphocyte autoantibody targets in this
disorder (7) were identified as isoforms of the CD45 molec-
ular complex (leukocyte common antigen) . Because different
isoforms ofCD45 define functionally important lymphocyte
subpopulations and are pivotal in T cell regulation of cell
signaling during the immune response via their protein tyro-
sine phosphatase activity (8-10), these data may be relevant
to basic mechanisms underlying immunologic dysfunction
in SLE and other autoimmune diseases .
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Materials and Methods
Patients and Serum.
￿
Venous blood was obtained from 43 patients
attending the University ofNorth Carolina Lupus Clinicwho met
the revised criteria of the American College ofRheumatology for
classification as SLE (11), and from 10 normal subjects. After sepa-
ration from blood, serum was aliquoted and stored at -70°C. Each
serum aliquot was heated at 56°C for 1 h immediately before use
to inactivate complement .
Cells. E6-1, a CD4+/CD45RA+/TCR-tx/a . Jurkat T cell
line phenotypically similar to resting peripheral lymphocytes, and
PEER, a CD4 -/CD8-/CD45R0+/TCR-a/f3+ cell line, were
cultured in RPMI 1640 medium containing 10% FCS, glutamine,
and antibiotics .
Special Immunological Reagents.
￿
T191, an IgG2a mAb to con-
ventional CD45 (12) was provided byDr. R. Mittler, Bristol-Meyers
Co., Wallingford, CT Anti-2144, a mAb to CD45RA (13), was
a gift from Dr. C. Morimoto, Harvard Medical School, Boston,
MA .UCHL1, amAb toCD45RO (14), was purchased from Dako
Corp., Santa Barbara, CA .
Indirect Immunofluorescence and Flow Cytometry.
￿
Binding ofr Abs
and SLE IgM to the T cell lines was detected by indirect im-
munofluorescence at 4°C using FITC-conjugated F(ab')2 goat
anti-mouse IgG or anti-human IgM (Chapel Laboratories, Coch-
ranville, PA) (1) .
Lectin Affinity Chromatography.
￿
Glycoproteins from E6-1 and
PEER were purified from 0.5% Renex 30 detergent cell lysates
by elution from agarose-conjugated wheat germ agglutinin (WGA)
(Vector Laboratories, Burlingame, CA) with 10% N-acetyl-
glucosamine (7) .
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￿
All isoforms ofCD45 were pre-cleared
from E6-1 and PEER WGA eluates by immunoprecipitation with
T191 and protein A-Sepharose (Zymed Laboratories, San Francisco,
CA), as described in detail previously (15). Control immunoprecipi-
tations were performed with UPC10, a monoclonal IgG2a. SLE
patient sera were depleted ofantilymphocyte antibodies by incuba-
tion with viable E6-1 cells, as described previously (7).
Electrophoresis andImmunoblotting .
￿
Detergent cell lysates, lectin
eluates, or -32-fold enriched plasma membranes (16) in Laemmli
sample buffer were subjected to electrophoresis on 6 or 8% SDS-
polyacrylamide slab gels under reducing conditions, and electro-
eluted to nitrocellulose . The blots were probed with appropriate
dilutions ofSLE patient serum or normal humanserum and stained
with biotinylated anti-human IgM or IgG antibodies (Tago Inc .,
Burlingame, CA) and avidin-biotinylated horseradish peroxidase
(Vectastain ABC kit ; Vector Laboratories, Inc., Burlingame, CA),
as described in detail previously (7, 15) .
Results and Discussion
Nearly one-third (10/29) of SLE patient sera positive for
IgM antilymphocyte antibodies against E6-1 in indirect im-
munofluorescence assays contained IgM that stained one or
more "400-kD proteins (gp -200) on blots ofE6-1 plasma
membranes or WGA-purified glycoproteins (Fig . 1 a) . IgM
antibodies to gp -200 were not demonstrable in 10 control
sera from normal subjects or in 14 antilymphocyte autoanti-
body-negative SLE sera . When blots of glycoproteins from
E6-1 and a second T cell line, PEER, were separated on 6%
SDS-polyacrylamide gels using extended electrophoresis times,
gp -200 was resolved into four proteins ofM r 180-220,000 .
As illustrated for representative SLEpatients in Fig . 1 b, anti-gp
Figure 1 .
￿
IgM antibodies in SLE patient sera recognize different
-200-kDT cell glycoproteins. (a) Equal concentrations of protein in
enriched plasma membranes (lane 1), whole cell lysate (lanes 2 and
4), or glycoproteins purified from E6-1 cells by WGA affinity chro-
matography (lane 3) were separated on 8% SDS-polyacrylamide gels,
blotted to nitrocellulose, and probed with IgM from SLE patients St
(lanes 1 and 2) and Wa (lanes 3 and 4), as described in Materials and
Methods. (b) Blots were prepared with E6-1 or PEER WGA eluates
separated on 6% SDS-polyacrylamide gels using prolonged elec-
trophoresis times, and probed with antilymphocyte antibody-positive
SLE sera (St, lanes 1, 6, and 7; Wa, lane 2 ; Le, lane 3 ; and Tu, lanes
8 and 9), antilymphocyte antibody-negative SLE serum (lane 4), or
normal human serum (lane 5) .
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-200-positive sera stained proteins of 190, 205, and/or 220
kD with E6-1 glycoproteins (lanes 1-3, 6), but, with one
exception, didnot react with PEER glycoproteins (e.g., com-
pare staining of E6-1 and PEER by St serum in lanes 6 and
7, respectively). Theexceptional serum (patient Tu)contained
IgM that stained several E6-1 proteins (lane 8) and a 180-kD
protein with PEER (lane 9) . The general absence of anti-gp
-200 reactivity with PEER glycoproteins in the panel of
SLE sera studied probably explains the dramatically lower
IgM indirect immunofluorescent staining of PEER (32 ±
19% IgM-stained cells) relative to E6-1 (62 ± 28% IgM-
stained cells) .
Thesimilarity between themolecularmass of thefour SLE
IgM antibody targets and that of the p220/p205/p190/pl80
isoforms ofCD45 known to be expressed on different popu-
lations of lymphocytes (17) suggested that the SLE IgM an-
tibodies were directed against individual isoforms ofCD45
expressed differently on E6-1 and PEER . In indirect im-
munofluorescence experiments to test this possibility, E6-1
was stained by T191, amAb that recognizes all CD45 iso-
forms, and by anti-2H4 (CD45RA specific), but not by
UCHL1 (CD45RO specific) ; conversely, PEER reactedwith
T191 and UCHL1, but notwith anti-2H4 . Taken together,
these data strongly suggested that the IgM anti-gp -200
antibodies in the SLE sera recognize specific isoforms ofCD45 .
The identity of gp -200 with CD45 was established by
depletingCD45 fromWGA eluates of E6-1 andPEER with
T191. Immunoblotsof CD45-depleted glycoproteinsno longer
were stained by SLE IgM (Fig . 2 a) . These data, together
with the results of the immunofluorescence experiments and
the informative staining patterns of Tu IgMforE6-1 andPEER
glycoproteins, indicate unequivocally that SLE IgM recog-
nized isoform-specific determinants of CD45 expressed on
the cell surface, rather than the intracytoplasmic domain of
Figure 2 .
￿
Extra-cytoplasmic domain specificity of IgM autoanti-
bodies in SLE sera for different isoforms of CD45 . (a) WGA eluates
of E6-1 or PEER were pre-cleared of CD45 with mAb T191 (even
lanes) or control IgG2a (odd lanes) and examined for residual reac-
tivity with SLE IgM by immunoblotting (patient McD, lanes 1 and
2 ; patient Tu, lanes 3 and 4) . (b) Serum from SLE patient Wa was
exhaustively absorbed with packed human erythrocytes, as a control
(lane 1), or viable E6-1 cells (lane 2) and then examined for residual
reactivity with CD45, as described in Materials and Methods .this molecule, which is identical among all isoforms. Con-
sistent with this interpretation was the observation that ex-
haustive absorption of SLE sera with viable E6-1 cells removed,
in parallel, both IgM antibody that stained CD45 on blots
and IgM staining of T cells by indirect immunofluorescence
(Fig. 2 b).
It is likely that anti-CD45 autoantibodies recognize amino
acid sequence determinants, at least in part, because glycosi-
dase F treatment of E6-1 glycoproteins, while reducing the
estimated molecular mass of the CD45 isoforms, did not ap-
preciably alter theircapacity to be stained with SLE IgM (data
not shown). Epitope mapping will be required to define ex-
actly the fine specificity of anti-CD45 autoantibodies, but
it can be deduced from the present data that at least some
of the reactive epitopes are distinct from those recognized
by anti-2H4 on p220/p205 and by UCHIA on p180. Thus,
of eight SLE sera studied in detail, four reacted only with
p220 and p205 CD45RA isoforms (13), but the other four
sera reacted with p205 alone (one serum), p220 alone (two
sera), p205, p120, and p180 (one serum), and p220, p205,
and p190 (one serum). Of interest, the dominant specificity
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